Blueberries Medical Corp. Announces C$1 Million Non-Brokered Private Placement

LOS ANGELES- Blueberries Medical Corp., a Latin American licensed producer of medicinal cannabis and cannabis-derived products, has announced a non-brokered private placement to raise approximately C$1.05 million (approximately US$740,000). ​

Offering Details

• Common Shares Issued: 96,064,935​

• Price per Share: C$0.011​

• Gross Proceeds: Approximately C$1.05 million​

• Expected Closing Date: On or about March 25, 2025​

The net proceeds from this offering are intended to fund and expand operations, as well as for general corporate and working capital purposes.

Participation by Terraflos Inc.

The offering is expected to be led by Terraflos Inc., a cannabis company operating throughout Latin America. Facundo Garreton, the Chairman, Chief Executive Officer, and a director of Blueberries, founded and controls Terraflos. Additionally, Guillermo Rodriguez, a director of Blueberries, is also expected to participate in the offering. ​

Regulatory Considerations

The participation of Terraflos and the aforementioned individuals constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. However, Blueberries is exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with this participation, relying on specific sections of MI 61-101. ​

Blueberries Medical Corp. operates primarily in the Bogotá Savannah of central Colombia and is licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis. The company combines expertise in agriculture, genetics, extraction, medicine, pharmacology, and marketing to position itself as a supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. ​